Company intelligence / Profile preview

Artemis 1

Cologne, NRW, Germanynasa.gov ↗

Ownership: Private
Development stage: Other

Overview

Artemis developed advanced genetically engineered mouse models and stem cell technologies that enabled pharmaceutical, biotech, and academic researchers to validate drug targets and study disease mechanisms. Their Conditional™ gene targeting allowed precise temporal/spatial control of gene inactivation. The company was recognized as a world leader in this field before being acquired by Exelixis in 2001 and later by Taconic Farms in 2007.

Therapeutic areas: Other
Modalities: Genetically engineered mouse models (GEMMs)Engineered mouse embryonic stem cellsshRNA-based gene knockdown models
Industry: Non-Drug Biotech

Partnerships

Merck & Co., Inc.

Beyond the preview

Go deeper on Artemis 1.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Artemis 1.

Explore the full profile